Selegiline
Brand: Eldepryl (US/EU) / Selgin (IN) / Selgine (BD)
Antiparkinson
MAO-B inhibitor
Pharmacokinetics
| Half-life | 10 hours |
| Tmax | 1 h |
| Bioavailability | 10 % (approx) |
| Protein Binding | 94 % |
| Volume of Distribution | 5 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Irreversible MAO-B inhibition; amphetamine metabolites present. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Insomnia, jitteriness, nausea, hypertension if combined with tyramine-rich foods
Contraindications:
Concurrent Meperidine / SSRIs / SNRIs / other MAO inhibitors
Precautions:
Avoid late evening dose (may cause insomnia due to amphetamine metabolites)